Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma

Published:2016-12-16 Issue:1 Volume:6 Page:36-44
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Foss Francine¹,Pro Barbara²,Miles Prince H.³,Sokol Lubomir⁴,Caballero Dolores⁵,Horwitz Steven⁶,Coiffier Bertrand⁷

Affiliation:

1. Yale Cancer Center; New Haven Connecticut

2. Thomas Jefferson University; Philadelphia Pennsylvania

3. Peter MacCallum Cancer Centre; University of Melbourne; Melbourne, Victoria Australia

4. Moffitt Cancer Center; Tampa Florida

5. Hospital Universitario de Salamanca; Salamanca Spain

6. Memorial Sloan Kettering Cancer Center; New York New York

7. Hospices Civils de Lyon; Lyon France

Funder

Celgene

National Institutes of Health

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Reference36 articles.

1. Management of peripheral T-cell non-Hodgkin's lymphoma;Horwitz;Curr. Opin. Oncol.,2007

2. American Cancer Society 2015

3. NCCN Clinical Practice Guidelines in Oncology

4. International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes;Vose;J. Clin. Oncol.,2008

5. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project;Savage;Blood,2008

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Distance between miRNA responsive elements selectively enhances target specificity with reduced cellular toxicity by miRNA-mediated synergism;2024-08-04

2. Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed/refractory T-cell lymphoma: results from a phase I/II open-label multicenter study;Haematologica;2023-07-13

3. Epigenetic targets in B- and T-cell lymphomas: latest developments;Therapeutic Advances in Hematology;2023-01

4. Safety considerations with the current treatments for peripheral T-cell lymphoma;Expert Opinion on Drug Safety;2022-02-06

5. Diagnosis, management and follow up of peripheral T cell lymphomas: A Consensus Practice Statement from the Australasian Lymphoma Alliance;Internal Medicine Journal;2021-10-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3